

# Franco Dallegri

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2173100/publications.pdf>

Version: 2024-02-01

203  
papers

6,598  
citations

66343

42  
h-index

91884

69  
g-index

204  
all docs

204  
docs citations

204  
times ranked

9130  
citing authors

#	ARTICLE	IF	CITATIONS
1	Atherosclerosis in Rheumatoid Arthritis: Promoters and Opponents. <i>Clinical Reviews in Allergy and Immunology</i> , 2020, 58, 1-14.	6.5	41
2	Antiapolipoprotein A-1 Autoantibody Positivity Is Associated with Threatened Abortion. <i>BioMed Research International</i> , 2020, 2020, 1-8.	1.9	0
3	Resistin is associated with overall survival in non-small cell lung cancer patients during nivolumab treatment. <i>Clinical and Translational Oncology</i> , 2020, 22, 1603-1610.	2.4	3
4	Platelet-to-lymphocyte ratio at the time of carotid endarterectomy is associated with acute coronary syndrome occurrence. <i>Journal of Cardiovascular Medicine</i> , 2020, 21, 80-82.	1.5	8
5	Radiologic Cerebral Reperfusion at 24h Predicts Good Clinical Outcome. <i>Translational Stroke Research</i> , 2019, 10, 178-188.	4.2	19
6	Baseline serum levels of osteopontin predict clinical response to treatment with nivolumab in patients with non-small cell lung cancer. <i>Clinical and Experimental Metastasis</i> , 2019, 36, 449-456.	3.3	15
7	Serum PCSK9 levels at the second nivolumab cycle predict overall survival in elderly patients with NSCLC: a pilot study. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1351-1358.	4.2	24
8	Impact of different ectopic fat depots on cardiovascular and metabolic diseases. <i>Journal of Cellular Physiology</i> , 2019, 234, 21630-21641.	4.1	128
9	Baseline hsCRP predicts hypertension remission in metabolic syndrome. <i>European Journal of Clinical Investigation</i> , 2019, 49, e13128.	3.4	24
10	Baseline neutrophil-to-lymphocyte ratio is associated with long-term T2D remission after metabolic surgery. <i>Acta Diabetologica</i> , 2019, 56, 741-748.	2.5	15
11	Novel findings in neutrophil biology and their impact on cardiovascular disease. <i>Cardiovascular Research</i> , 2019, 115, 1266-1285.	3.8	118
12	Serum osteopontin negatively impacts on intima-media thickness in patients with systemic lupus erythematosus. <i>European Journal of Clinical Investigation</i> , 2019, 49, e13089.	3.4	8
13	Pre-surgery age-adjusted Charlson Comorbidity Index is associated with worse outcomes in acute cholecystitis. <i>Digestive and Liver Disease</i> , 2019, 51, 858-863.	0.9	25
14	Serum levels of osteopontin predict diabetes remission after bariatric surgery. <i>Diabetes and Metabolism</i> , 2019, 45, 356-362.	2.9	20
15	Epicardial adipose tissue and cardiovascular diseases. <i>International Journal of Cardiology</i> , 2019, 278, 254-260.	1.7	147
16	Impact of Red Wine Consumption on Cardiovascular Health. <i>Current Medicinal Chemistry</i> , 2019, 26, 3542-3566.	2.4	44
17	Diabetes and Vascular Disease: Is It All About Glycemia?. <i>Current Pharmaceutical Design</i> , 2019, 25, 3112-3127.	1.9	14
18	High serum levels of C-reactive protein (CRP) predict beneficial decrease of visceral fat in obese females after sleeve gastrectomy. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2018, 28, 494-500.	2.6	26

#	ARTICLE	IF	CITATIONS
19	Serum levels of osteopontin predict major adverse cardiovascular events in patients with severe carotid artery stenosis. <i>International Journal of Cardiology</i> , 2018, 255, 195-199.	1.7	40
20	Short-term effect of rosuvastatin treatment on arterial stiffness in individuals with newly-diagnosed heterozygous familial hypercholesterolemia. <i>International Journal of Cardiology</i> , 2018, 255, 215-220.	1.7	6
21	Serum lipoprotein (a) predicts acute coronary syndromes in patients with severe carotid stenosis. <i>European Journal of Clinical Investigation</i> , 2018, 48, e12888.	3.4	13
22	Levels of serum uric acid at admission for hypoglycaemia predict 1-year mortality. <i>Acta Diabetologica</i> , 2018, 55, 323-330.	2.5	5
23	Serum adiponectin levels predict acute coronary syndrome (ACS) in patients with severe carotid stenosis. <i>Vascular Pharmacology</i> , 2018, 102, 37-43.	2.1	21
24	The Pathophysiological Role of Neutrophil Extracellular Traps in Inflammatory Diseases. <i>Thrombosis and Haemostasis</i> , 2018, 118, 006-027.	3.4	106
25	Obesity phenotypes and their paradoxical association with cardiovascular diseases. <i>European Journal of Internal Medicine</i> , 2018, 48, 6-17.	2.2	202
26	C-Reactive Protein Levels at the Midpregnancy Can Predict Gestational Complications. <i>BioMed Research International</i> , 2018, 2018, 1-8.	1.9	21
27	Resistin exerts a beneficial role in atherosclerotic plaque inflammation by inhibiting neutrophil migration. <i>International Journal of Cardiology</i> , 2018, 272, 13-19.	1.7	25
28	Reduction in TIMP-2 serum levels predicts remission of inflammatory bowel diseases. <i>European Journal of Clinical Investigation</i> , 2018, 48, e13002.	3.4	13
29	Serum PCSK9 levels predict the occurrence of acute coronary syndromes in patients with severe carotid artery stenosis. <i>International Journal of Cardiology</i> , 2018, 263, 138-141.	1.7	20
30	The Role of Adipocytokines in Coronary Atherosclerosis. <i>Current Atherosclerosis Reports</i> , 2017, 19, 10.	4.8	67
31	High baseline C-reactive protein levels predict partial type 2 diabetes mellitus remission after biliopancreatic diversion. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2017, 27, 423-429.	2.6	11
32	The Role of Inflammation in Cardiovascular Outcome. <i>Current Atherosclerosis Reports</i> , 2017, 19, 11.	4.8	101
33	Alamandine abrogates neutrophil degranulation in atherosclerotic mice. <i>European Journal of Clinical Investigation</i> , 2017, 47, 117-128.	3.4	15
34	Plasma palmitoylethanolamide (PEA) as a potential biomarker for impaired coronary function. <i>International Journal of Cardiology</i> , 2017, 231, 1-5.	1.7	11
35	Update on the role of Pentraxin 3 in atherosclerosis and cardiovascular diseases. <i>Vascular Pharmacology</i> , 2017, 99, 1-12.	2.1	69
36	Early reduction of matrix metalloproteinase-8 serum levels is associated with leptin drop and predicts diabetes remission after bariatric surgery. <i>International Journal of Cardiology</i> , 2017, 245, 257-262.	1.7	19

#	ARTICLE	IF	CITATIONS
37	Monocyte count at onset predicts poststroke outcomes during a 90-day follow-up. <i>European Journal of Clinical Investigation</i> , 2017, 47, 702-710.	3.4	30
38	Low serum C-reactive protein levels predict 90-day mortality in hypoglycaemic patients. <i>Diabetes and Metabolism</i> , 2017, 43, 554-556.	2.9	4
39	Comment on "Costs associated with emergency care and hospitalization for severe hypoglycemia". <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2017, 27, 86-87.	2.6	0
40	Pathophysiological relevance of macrophage subsets in atherogenesis. <i>Thrombosis and Haemostasis</i> , 2017, 117, 07-18.	3.4	77
41	Sepsis by <i>Pasteurella multocida</i> in an Elderly Immunocompetent Patient after a Cat Bite. <i>Case Reports in Infectious Diseases</i> , 2017, 2017, 1-4.	0.5	4
42	Treatment with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors to Reduce Cardiovascular Inflammation and Outcomes. <i>Current Medicinal Chemistry</i> , 2017, 24, 1403-1416.	2.4	44
43	Intraplaque Expression of C-Reactive Protein Predicts Cardiovascular Events in Patients with Severe Atherosclerotic Carotid Artery Stenosis. <i>Mediators of Inflammation</i> , 2016, 2016, 1-10.	3.0	17
44	Update on Inflammatory Biomarkers and Treatments in Ischemic Stroke. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1967.	4.1	121
45	Treatment with the GPR55 antagonist CID16020046 increases neutrophil activation in mouse atherogenesis. <i>Thrombosis and Haemostasis</i> , 2016, 116, 987-997.	3.4	28
46	Anti-apolipoprotein A-1 auto-antibodies as active modulators of atherothrombosis. <i>Thrombosis and Haemostasis</i> , 2016, 116, 554-564.	3.4	20
47	Anti-ApoA1 IgG serum levels predict worse poststroke outcomes. <i>European Journal of Clinical Investigation</i> , 2016, 46, 805-817.	3.4	17
48	Cellular recruitment in myocardial ischaemia/reperfusion injury. <i>European Journal of Clinical Investigation</i> , 2016, 46, 590-601.	3.4	82
49	Update on the effects of treatment with recombinant tissue-type plasminogen activator (rt-PA) in acute ischemic stroke. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 1323-1340.	3.1	15
50	Vitamin D receptor is expressed within human carotid plaques and correlates with pro-inflammatory M1 macrophages. <i>Vascular Pharmacology</i> , 2016, 85, 57-65.	2.1	20
51	Decreased serum PCSK9 levels after ischaemic stroke predict worse outcomes. <i>European Journal of Clinical Investigation</i> , 2016, 46, 1053-1062.	3.4	9
52	Role of neutrophils in atherogenesis: an update. <i>European Journal of Clinical Investigation</i> , 2016, 46, 252-263.	3.4	32
53	Leptin/adiponectin ratio predicts poststroke neurological outcome. <i>European Journal of Clinical Investigation</i> , 2015, 45, 1184-1191.	3.4	20
54	Anti-apoA-1 auto-antibodies increase mouse atherosclerotic plaque vulnerability, myocardial necrosis and mortality triggering TLR2 and TLR4. <i>Thrombosis and Haemostasis</i> , 2015, 114, 410-422.	3.4	36

#	ARTICLE	IF	CITATIONS
55	Treatment with recombinant tissue plasminogen activator (r-TPA) induces neutrophil degranulation in vitro via defined pathways. <i>Vascular Pharmacology</i> , 2015, 64, 16-27.	2.1	42
56	Treatment with sulphated galactan inhibits macrophage chemotaxis and reduces intraplaque macrophage content in atherosclerotic mice. <i>Vascular Pharmacology</i> , 2015, 71, 84-92.	2.1	7
57	Serum osteopontin levels are upregulated and predict disability after an ischaemic stroke. <i>European Journal of Clinical Investigation</i> , 2015, 45, 579-586.	3.4	40
58	Treatment with KLEPTOSEÂ® CRYSMEB reduces mouse atherogenesis by impacting on lipid profile and Th1 lymphocyte response. <i>Vascular Pharmacology</i> , 2015, 72, 197-208.	2.1	14
59	Nicotinamide phosphoribosyltransferase inhibition reduces intraplaque CXCL1 production and associated neutrophil infiltration in atherosclerotic mice. <i>Thrombosis and Haemostasis</i> , 2014, 112, 308-322.	3.4	44
60	Carotid atherosclerotic plaque stenosis: the stabilizing role of statins. <i>European Journal of Clinical Investigation</i> , 2014, 44, 1122-1134.	3.4	33
61	Statin Treatment Is Associated with Reduction in Serum Levels of Receptor Activator of NF- $\kappa$ B Ligand and Neutrophil Activation in Patients with Severe Carotid Stenosis. <i>Mediators of Inflammation</i> , 2014, 2014, 1-11.	3.0	26
62	Treatment with Evasin-3 abrogates neutrophil-mediated inflammation in mouse acute pancreatitis. <i>European Journal of Clinical Investigation</i> , 2014, 44, 940-950.	3.4	42
63	Angiotensin II receptor antagonists in acute coronary syndromes. <i>European Journal of Clinical Investigation</i> , 2014, 44, 219-230.	3.4	7
64	Neutrophil migration towards CXCL5 and CXCL8 is prevented by non-steroidal anti-inflammatory drugs via inhibition of different pathways. <i>British Journal of Pharmacology</i> , 2014, 171, 3376-3393.	5.4	29
65	Treatment with Angiotensin-(1-7) reduces inflammation in carotid atherosclerotic plaques. <i>Thrombosis and Haemostasis</i> , 2014, 111, 736-747.	3.4	47
66	Inhibition of Nicotinamide Phosphoribosyltransferase Reduces Neutrophil-Mediated Injury in Myocardial Infarction. <i>Antioxidants and Redox Signaling</i> , 2013, 18, 630-641.	5.4	95
67	Serum levels of anti-apolipoprotein A-1 auto-antibodies and myeloperoxidase as predictors of major adverse cardiovascular events after carotid endarterectomy. <i>Thrombosis and Haemostasis</i> , 2013, 109, 706-715.	3.4	48
68	Update on the Pathophysiological Activities of the Cardiac Molecule Cardiotrophin-1 in Obesity. <i>Mediators of Inflammation</i> , 2013, 2013, 1-8.	3.0	5
69	Treatment with Evasin-3 Reduces Atherosclerotic Vulnerability for Ischemic Stroke, but Not Brain Injury in Mice. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2013, 33, 490-498.	4.3	55
70	Update on the Protective Molecular Pathways Improving Pancreatic Beta-Cell Dysfunction. <i>Mediators of Inflammation</i> , 2013, 2013, 1-14.	3.0	22
71	Role of Mitogen-Activated Protein Kinase Pathways in Multifactorial Adverse Cardiac Remodeling Associated with Metabolic Syndrome. <i>Mediators of Inflammation</i> , 2013, 2013, 1-11.	3.0	24
72	The activation of the cannabinoid receptor type 2 reduces neutrophilic protease-mediated vulnerability in atherosclerotic plaques. <i>European Heart Journal</i> , 2012, 33, 846-856.	2.2	81

#	ARTICLE	IF	CITATIONS
73	Renin-Angiotensin Antagonists: Therapeutic Effects Beyond Blood Pressure Control?. <i>Current Pharmaceutical Design</i> , 2012, 18, 1011-1020.	1.9	9
74	Anti-Inflammatory Approaches to Reduce Acute Cardiovascular Events: Not Only Benefits. <i>Current Pharmaceutical Biotechnology</i> , 2012, 13, 27-36.	1.6	1
75	Classical and New Renin-Angiotensin Signalling in Atherosclerosis. <i>Current Signal Transduction Therapy</i> , 2012, 7, 111-119.	0.5	2
76	Receptor activator of NF- $\kappa$ B ligand (RANKL) increases the release of neutrophil products associated with coronary vulnerability. <i>Thrombosis and Haemostasis</i> , 2012, 107, 124-139.	3.4	34
77	Endothelial and Smooth Muscle Cells from Abdominal Aortic Aneurysm Have Increased Oxidative Stress and Telomere Attrition. <i>PLoS ONE</i> , 2012, 7, e35312.	2.5	87
78	Exocytosis of azurophil and arginase 1-containing granules by activated polymorphonuclear neutrophils is required to inhibit T lymphocyte proliferation. <i>Journal of Leukocyte Biology</i> , 2011, 89, 721-727.	3.3	106
79	CC and CXC chemokines are pivotal mediators of cerebral injury in ischaemic stroke. <i>Thrombosis and Haemostasis</i> , 2011, 105, 409-420.	3.4	119
80	Anti-Apolipoprotein A-1 auto-antibodies are active mediators of atherosclerotic plaque vulnerability. <i>European Heart Journal</i> , 2011, 32, 412-421.	2.2	110
81	Acipimox reduces circulating levels of insulin and associated neutrophilic inflammation in metabolic syndrome. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2011, 300, E681-E690.	3.5	17
82	New evidence for nicotinic acid treatment to reduce atherosclerosis. <i>Expert Review of Cardiovascular Therapy</i> , 2010, 8, 1457-1467.	1.5	14
83	Coronary artery calcification and cardiovascular risk: the role of RANKL/OPG signalling. <i>European Journal of Clinical Investigation</i> , 2010, 40, 645-654.	3.4	22
84	Receptor Activator of Nuclear Factor Kappa B Ligand/Osteoprotegerin Pathway Is a Promising Target to Reduce Atherosclerotic Plaque Calcification. <i>Critical Pathways in Cardiology</i> , 2010, 9, 227-230.	0.5	13
85	Systemic and Intraplaque Mediators of Inflammation Are Increased in Patients Symptomatic for Ischemic Stroke. <i>Stroke</i> , 2010, 41, 1394-1404.	2.0	106
86	Oxaprozin-Induced Apoptosis on CD40 Ligand-Treated Human Primary Monocytes Is Associated with the Modulation of Defined Intracellular Pathways. <i>Journal of Biomedicine and Biotechnology</i> , 2009, 2009, 1-9.	3.0	3
87	Intestinal Radiation-Induced Stricture Favours Small Bowel Obstruction by Phytobezoar: Report of a Case. <i>Gastroenterology Research and Practice</i> , 2009, 2009, 1-4.	1.5	8
88	Antiproliferative and Proapoptotic Activities of a New Class of Pyrazole Derivatives in HL60 Cells. <i>Chemistry and Biodiversity</i> , 2009, 6, 1674-1687.	2.1	30
89	Sulphasalazine accelerates apoptosis in neutrophils exposed to immune complex: Role of caspase pathway. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2009, 36, 1132-1135.	1.9	10
90	Chlorhexidine prevents hypochlorous acid-induced inactivation of $\alpha$ -1 antitrypsin. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2009, 36, e72-7.	1.9	13

#	ARTICLE	IF	CITATIONS
91	Delayed apoptosis of human monocytes exposed to immune complexes is reversed by oxaprozin: role of the Akt/I $\kappa$ B kinase/nuclear factor $\kappa$ B pathway. <i>British Journal of Pharmacology</i> , 2009, 157, 294-306.	5.4	18
92	6-Amino-4-oxo-1,3-diphenyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carbonyl derivatives as a new class of potent inhibitors of Interleukin-8-induced neutrophil chemotaxis. <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 3580-3587.	3.0	7
93	Induction of neutrophil respiratory burst by tumour necrosis factor-alpha; priming effect of solid-phase fibronectin and intervention of CD 11b-CD18 integrins. <i>Clinical and Experimental Immunology</i> , 2008, 94, 533-538.	2.6	37
94	Cyclic AMP-elevating agents down-regulate the oxidative burst induced by granulocyte-macrophage colony-stimulating factor (GM-CSF) in adherent neutrophils. <i>Clinical and Experimental Immunology</i> , 2008, 101, 502-506.	2.6	47
95	Tumor necrosis factor-alpha (TNF- $\alpha$ ) induces integrin CD11b/CD18 (Mac-1) up-regulation and migration to the CC chemokine CCL3 (MIP-1 $\alpha$ ) on human neutrophils through defined signalling pathways. <i>Cellular Signalling</i> , 2008, 20, 557-568.	3.6	107
96	Human Mesenchymal Stem Cells Inhibit Neutrophil Apoptosis: A Model for Neutrophil Preservation in the Bone Marrow Niche. <i>Stem Cells</i> , 2008, 26, 151-162.	3.2	442
97	Synthesis and Biological Evaluation of <i>N</i> -Pyrazolyl- <i>N</i> -alkyl/benzyl/phenylureas: a New Class of Potent Inhibitors of Interleukin 8-Induced Neutrophil Chemotaxis. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 3618-3626.	6.4	24
98	Nonleukoreduced red blood cell transfusion induces a sustained inhibition of neutrophil chemotaxis by stimulating in vivo production of transforming growth factor- $\beta$ 1 by neutrophils: role of the immunoglobulinlike transcript 1, sFasL, and sHLA-I. <i>Transfusion</i> , 2007, 47, 1395-1404.	1.6	30
99	Nephrotic syndrome in a patient with IgM myeloma with associated neutrophilia. <i>European Journal of Haematology</i> , 2007, 79, 76-80.	2.2	7
100	Immune Complexes Induce Monocyte Survival through Defined Intracellular Pathways. <i>Annals of the New York Academy of Sciences</i> , 2007, 1095, 209-219.	3.8	8
101	Lymphoproliferative Disorders and Chemokines. <i>Current Drug Targets</i> , 2006, 7, 81-90.	2.1	12
102	Synthesis and biological evaluation of novel heterocyclic ionone-like derivatives as anti-inflammatory agents. <i>Bioorganic and Medicinal Chemistry</i> , 2006, 14, 5152-5160.	3.0	42
103	Chemokine receptor expression and function in childhood acute lymphoblastic leukemia of B-lineage. <i>Leukemia Research</i> , 2006, 30, 365-372.	0.8	31
104	Induction of Neutrophil Chemotaxis by Leptin: Crucial Role for p38 and Src Kinases. <i>Annals of the New York Academy of Sciences</i> , 2006, 1069, 463-471.	3.8	78
105	Insulin Primes Human Neutrophils for CCL3-Induced Migration: Crucial Role for JNK 1/2. <i>Annals of the New York Academy of Sciences</i> , 2006, 1090, 399-407.	3.8	11
106	Dexamethasone-Induced Apoptosis of Human Monocytes Exposed to Immune Complexes. Intervention of CD95-and Xiap-Dependent Pathways. <i>International Journal of Immunopathology and Pharmacology</i> , 2005, 18, 403-415.	2.1	18
107	CCL3 (MIP-1 $\alpha$ ) induces in vitro migration of GM-CSF-primed human neutrophils via CCR5-dependent activation of ERK 1/2. <i>Cellular Signalling</i> , 2005, 17, 355-363.	3.6	50
108	Pharmacological properties of nimesulide. , 2005, , 133-244.		4

#	ARTICLE	IF	CITATIONS
109	A review of the emerging profile of the anti-inflammatory drug oxaprozin. Expert Opinion on Pharmacotherapy, 2005, 6, 777-785.	1.8	16
110	CCL19 and CXCL12 Trigger in Vitro Chemotaxis of Human Mantle Cell Lymphoma B Cells. Clinical Cancer Research, 2004, 10, 964-971.	7.0	64
111	Oxidative Stress Mediates Apoptotic Changes Induced by Hyperglycemia in Human Tubular Kidney Cells. Journal of the American Society of Nephrology: JASN, 2004, 15, 85S-87.	6.1	77
112	Monoclonal LYM-1 antibody-dependent cytolysis by human neutrophils exposed to GM-CSF: auto-regulation of target cell attack by cathepsin G. Journal of Leukocyte Biology, 2004, 75, 99-105.	3.3	15
113	Synthesis and biological evaluation of neutrophilic inflammation inhibitors. Il Farmaco, 2004, 59, 223-235.	0.9	14
114	Synthesis and Biological Evaluation of Neutrophilic Inflammation Inhibitors.. ChemInform, 2004, 35, no.	0.0	0
115	Leptin as a Uremic Toxin Interferes with Neutrophil Chemotaxis. Journal of the American Society of Nephrology: JASN, 2004, 15, 2366-2372.	6.1	78
116	In vitro inhibition of human neutrophil histotoxicity by ambroxol: evidence for a multistep mechanism. British Journal of Pharmacology, 2003, 140, 736-742.	5.4	12
117	Transforming growth factor $\beta$ 1 in supernatants from stored red blood cells inhibits neutrophil locomotion. Blood, 2003, 102, 1100-1107.	1.4	35
118	Synovial fluid from patients with rheumatoid arthritis inhibits neutrophil apoptosis: role of adenosine and proinflammatory cytokines. British Journal of Rheumatology, 2002, 41, 1249-1260.	2.3	68
119	Chemotaxis of human tonsil B lymphocytes to CC chemokine receptor (CCR) 1, CCR2 and CCR4 ligands is restricted to non-germinal center cells. International Immunology, 2002, 14, 883-892.	4.0	39
120	Taurine Prevents Apoptosis Induced by High Ambient Glucose in Human Tubule Renal Cells. Journal of Investigative Medicine, 2002, 50, 443-451.	1.6	87
121	Taurine Prevents Apoptosis Induced by High Ambient Glucose in Human Tubule Renal Cells. Journal of Investigative Medicine, 2002, 50, 443-451.	1.6	2
122	Pharmacological implications in the switch from acute to chronic inflammation. Inflammopharmacology, 2002, 10, 159-171.	3.9	8
123	Differential regulation of spontaneous and immune complex-induced neutrophil apoptosis by proinflammatory cytokines. Role of oxidants, Bax and caspase-3. Journal of Leukocyte Biology, 2002, 72, 125-32.	3.3	51
124	Chimaeric Lym-1 monoclonal antibody-mediated cytolysis by neutrophils from G-CSF-treated patients: stimulation by GM-CSF and role of Fc $\gamma$ 3-receptors. British Journal of Cancer, 2001, 85, 463-469.	6.4	14
125	Immune complex stimulation of neutrophil apoptosis: investigating the involvement of oxidative and nonoxidative pathways. Free Radical Biology and Medicine, 2001, 30, 161-169.	2.9	36
126	Stromal Cell-Derived Factor-1 as a Chemoattractant for Follicular Center Lymphoma B Cells. Journal of the National Cancer Institute, 2000, 92, 628-635.	6.3	92



#	ARTICLE	IF	CITATIONS
127	Spontaneous apoptosis in neutrophils is associated with downregulation of HLA Class I and is prevented by ligation of Class I. <i>Journal of Leukocyte Biology</i> , 2000, 68, 873-80.	3.3	7
128	Cefoperazone Prevents the Inactivation of $\alpha$ -Antitrypsin by Activated Neutrophils. <i>Antimicrobial Agents and Chemotherapy</i> , 1999, 43, 2307-2310.	3.2	12
129	Monoclonal Lym-1 Antibody-Dependent Cytolysis by Neutrophils Exposed to Granulocyte-Macrophage Colony-Stimulating Factor: Intervention of Fc $\gamma$ RII (CD32), CD11b-CD18 Integrins, and CD66b Glycoproteins. <i>Blood</i> , 1999, 93, 3505-3511.	1.4	35
130	FMLP- and TNF-stimulated monoclonal Lym-1 antibody-dependent lysis of B lymphoblastoid tumour targets by neutrophils. <i>British Journal of Cancer</i> , 1999, 80, 331-337.	6.4	6
131	Chemoattractant-induced release of elastase by tumor necrosis factor-primed human neutrophils: Auto-regulation by endogenous adenosine. <i>Inflammation Research</i> , 1999, 48, 637-642.	4.0	10
132	Soluble Fas ligand is chemotactic for human neutrophilic polymorphonuclear leukocytes. <i>Journal of Immunology</i> , 1999, 162, 3601-6.	0.8	121
133	Monoclonal Lym-1 antibody-dependent cytolysis by neutrophils exposed to granulocyte-macrophage colony-stimulating factor: intervention of Fc $\gamma$ RII (CD32), CD11b-CD18 integrins, and CD66b glycoproteins. <i>Blood</i> , 1999, 93, 3505-11.	1.4	6
134	Letter to the Editor. <i>Inflammation Research</i> , 1998, 47, 237-238.	4.0	1
135	Activation of neutrophil respiratory burst by cytokines and chemoattractants. Regulatory role of extracellular matrix glycoproteins. <i>Inflammation Research</i> , 1998, 47, 345-350.	4.0	24
136	Prostaglandin E2 inhibits apoptosis in human neutrophilic polymorphonuclear leukocytes: role of intracellular cyclic AMP levels. <i>Experimental Hematology</i> , 1998, 26, 895-902.	0.4	51
137	Recombinant Tumor Necrosis Factor Enhances the Locomotion of Memory and Naive B Lymphocytes From Human Tonsils Through the Selective Engagement of the Type II Receptor. <i>Blood</i> , 1997, 90, 4493-4501.	1.4	24
138	Chemoattractant-induced release of elastase by lipopolysaccharide (LPS)-primed neutrophils; inhibitory effect of the anti-inflammatory drug nimesulide. <i>Clinical and Experimental Immunology</i> , 1997, 110, 139-143.	2.6	13
139	Tumor Necrosis Factor (TNF) Enhances the Locomotion of Low-Density Human Tonsillar B Lymphocytes through the Selective Triggering of Type II Receptor. <i>Annals of the New York Academy of Sciences</i> , 1997, 815, 364-366.	3.8	0
140	Tissue injury in neutrophilic inflammation. <i>Inflammation Research</i> , 1997, 46, 382-391.	4.0	180
141	Chemoattractant-induced release of elastase by lipopolysaccharide (LPS)-primed neutrophils; inhibitory effect of the anti-inflammatory drug nimesulide. <i>Clinical and Experimental Immunology</i> , 1997, 110, 139-43.	2.6	7
142	Chemoattractant-induced release of elastase by lipopolysaccharide (LPS)-primed neutrophils; inhibitory effect of the anti-inflammatory drug nimesulide. <i>Clinical and Experimental Immunology</i> , 1997, 110, 139-143.	2.6	9
143	Inhibitory effect of salmeterol on the respiratory burst of adherent human neutrophils. <i>Clinical and Experimental Immunology</i> , 1996, 106, 97-102.	2.6	37
144	Monoclonal Lym-1 antibody-dependent lysis of B-lymphoblastoid tumor targets by human complement and cytokine-exposed mononuclear and neutrophilic polymorphonuclear leukocytes. <i>Blood</i> , 1996, 87, 5171-5178.	1.4	35

#	ARTICLE	IF	CITATIONS
145	Monoclonal Lym-1 antibody-dependent lysis of B-lymphoblastoid tumor targets by human complement and cytokine-exposed mononuclear and neutrophilic polymorphonuclear leukocytes. <i>Blood</i> , 1996, 87, 5171-8.	1.4	9
146	Sulphonamides as Anti-Inflammatory Agents: Old Drugs for New Therapeutic Strategies in Neutrophilic Inflammation?. <i>Clinical Science</i> , 1995, 88, 331-336.	4.3	33
147	Tumour necrosis factor alpha-induced oxidative burst in neutrophils adherent to fibronectin: effects of cyclic AMP-elevating agents. <i>British Journal of Haematology</i> , 1995, 91, 566-570.	2.5	44
148	Neutrophil dysfunction and increased susceptibility to infection. <i>European Journal of Clinical Investigation</i> , 1995, 25, 687-692.	3.4	31
149	Possible modes of action of nimesulide in controlling neutrophilic inflammation. <i>Arzneimittelforschung</i> , 1995, 45, 1114-7.	0.4	4
150	The Anti-Inflammatory Drug Nimesulide Inhibits Neutrophil Adherence to and Migration Across Monolayers of Cytokine-Activated Endothelial Cells. <i>Respiration</i> , 1994, 61, 336-341.	2.6	21
151	Triggering of respiratory burst by tumor necrosis factor in neutrophils adherent to fibronectin. Evidence for a crucial role of CD18 glycoproteins. <i>Agents and Actions</i> , 1994, 41, 57-61.	0.7	7
152	Nimesulide decreases superoxide production by inhibiting phosphodiesterase type IV. <i>European Journal of Pharmacology</i> , 1994, 268, 415-423.	2.6	66
153	Proteolytic inactivation of alpha-1-antitrypsin by human neutrophils: involvement of multiple and interlinked cell responses to phagocytosable targets. <i>European Journal of Clinical Investigation</i> , 1994, 24, 42-49.	3.4	42
154	Nimesulide as a Downregulator of the Activity of the Neutrophil Myeloperoxidase Pathway. <i>Drugs</i> , 1993, 46, 29-33.	10.9	20
155	Inactivation of Alpha-1-Proteinase Inhibitor by Neutrophil Metalloproteinases. <i>Respiration</i> , 1993, 60, 32-37.	2.6	26
156	The Anti-Inflammatory Drug Nimesulide Rescues Alpha-1-Proteinase Inhibitor from Oxidative Inactivation by Phagocytosing Neutrophils. <i>Respiration</i> , 1992, 59, 1-4.	2.6	16
157	The Drug 5-Aminosalicylic Acid Rescues $\alpha$ -1-Proteinase Inhibitor from the Neutrophil Oxidative Inactivation. <i>Digestion</i> , 1992, 51, 140-145.	2.3	13
158	Inhibition of the neutrophil oxidative response induced by the oral administration of nimesulide in normal volunteers. <i>Journal of Clinical &amp; Laboratory Immunology</i> , 1992, 37, 91-6.	0.1	6
159	Effect of nonsteroidal antiinflammatory drugs on the neutrophil promoted inactivation of alpha-1-proteinase inhibitor. <i>Journal of Rheumatology</i> , 1992, 19, 419-23.	2.0	11
160	Suppression of Neutrophil Chloramine Production by Nimesulide. <i>Drug Investigation</i> , 1991, 3, 75-78.	0.6	4
161	Cytoprotection against neutrophil-delivered oxidant attack by antibiotics. <i>Biochemical Pharmacology</i> , 1991, 42, 2317-2321.	4.4	18
162	Tumor cell lysis by activated human neutrophils: Analysis of neutrophil-delivered oxidative attack and role of leukocyte function-associated antigen 1. <i>Inflammation</i> , 1991, 15, 15-30.	3.8	58

#	ARTICLE	IF	CITATIONS
163	Cytoprotection against neutrophil derived hypochlorous acid: a potential mechanism for the therapeutic action of 5-aminosalicylic acid in ulcerative colitis.. Gut, 1990, 31, 184-186.	12.1	72
164	Neutrophils as Effectors of Host Defense and Host Damage. Physiopathology and Perspectives of Pharmacological Manipulation. International Journal of Immunopathology and Pharmacology, 1989, 2, 67-73.	2.1	1
165	Platelets as inhibitory cells in neutrophil-mediated cytolysis. Translational Research, 1989, 114, 502-9.	2.3	12
166	Visceral leishmaniasis: An opportunistic infection in AIDS. Clinical Immunology Newsletter, 1987, 8, 72-73.	0.1	0
167	Augmentation of neutrophil-mediated erythrocyte lysis by cells derived in vitro from human monocytes. Blood, 1987, 70, 1743-1749.	1.4	22
168	Antibody-dependent tumour cytolysis by human neutrophils: effect of synthetic serine esterase inhibitors and substrates. Immunology, 1987, 62, 387-91.	4.4	5
169	Relationship between antibody-dependent tumour cell lysis and primary granule exocytosis by human neutrophils. Clinical and Experimental Immunology, 1987, 70, 479-83.	2.6	16
170	Inhibition of neutrophil cytolysin production by target cells. Blood, 1986, 67, 1265-1272.	1.4	18
171	Expression of cytolytic functions in HL-60 leukaemic cells after induction of polymorphonuclear leukocyte differentiation. Blut, 1986, 52, 243-248.	1.2	1
172	Interference of target cell catalase with an early step of the neutrophil cytolytic pathway. Clinical and Experimental Immunology, 1986, 65, 664-70.	2.6	1
173	Cellular cytotoxicity mediated by granule-depleted neutrophil cytoplasts. Blut, 1985, 51, 97-102.	1.2	4
174	Restoration of defective EAG-rosetting capacity of cancer patient neutrophils by levamisole. Cancer, 1985, 55, 1668-1672.	4.1	5
175	Down-regulation of K cell activity by neutrophils. Blood, 1985, 65, 571-577.	1.4	12
176	Erythrocyte lysis by PMA-triggered neutrophil polymorphonuclears: evidence for an hypochlorous acid-dependent process. Immunology, 1985, 55, 639-45.	4.4	19
177	Defective neutrophil mobilization to skin chambers in cancer patients. Journal of Cancer Research and Clinical Oncology, 1984, 107, 53-56.	2.5	6
178	Extracellular cytolysis by leukaemic blast cells. British Journal of Haematology, 1984, 56, 147-152.	2.5	3
179	Neutropenia and impaired neutrophil function in glycogenosis type Ib. Journal of Inherited Metabolic Disease, 1984, 7, 151-154.	3.6	29
180	Neutrophil-mediated cellular cytotoxicity triggered by immobilized aggregated IgG: An in vitro model of cell injury during immune complex diseases. Journal of Clinical Immunology, 1984, 4, 439-444.	3.8	6

#	ARTICLE	IF	CITATIONS
181	Target cell lysis mediated by concanavalin A-triggered human neutrophils. <i>Blut</i> , 1984, 48, 147-152.	1.2	3
182	Antibody-Dependent Killing of Tumor Cells by Polymorphonuclear Leukocytes. Involvement of Oxidative and Nonoxidative Mechanisms <sup>23</sup> . <i>Journal of the National Cancer Institute</i> , 1984, 73, 331-339.	6.3	44
183	Ox Erythrocyte Cytotoxicity by Phorbol Myristate Acetate-Activated Human Neutrophils. <i>Scandinavian Journal of Immunology</i> , 1983, 17, 109-114.	2.7	11
184	Modulation of neutrophil Fc and C3b receptors. <i>Inflammation</i> , 1983, 7, 155-168.	3.8	11
185	Mechanisms of tumour cell destruction by PMA-activated human neutrophils. <i>Immunology</i> , 1983, 48, 273-9.	4.4	27
186	Neutrophil-mediated antibody-dependent cellular cytotoxicity against erythrocytes. Mechanisms of target cell destruction. <i>Clinical and Experimental Immunology</i> , 1983, 52, 613-9.	2.6	9
187	Disorders of neutrophil function in children with recurrent pyogenic infections. <i>Medical Microbiology and Immunology</i> , 1982, 171, 113-122.	4.8	11
188	Antibody-dependent cellular cytotoxicity of leukaemic blast cells and neutrophils from patients with acute myelogenous leukaemia. <i>Clinical and Experimental Immunology</i> , 1982, 47, 414-8.	2.6	7
189	Role of the oxidative metabolic burst in the antibody-dependent cellular cytotoxicity mediated by neutrophil polymorphonuclears. <i>Experimental Hematology</i> , 1982, 10, 859-66.	0.4	5
190	Effects of &lt;i>N</i>-(-2-Mercaptopropionyl) Glycine on Neutrophil Locomotion. <i>International Archives of Allergy and Immunology</i> , 1981, 64, 259-265.	2.1	2
191	Stimulation of neutrophil chemotaxis, adhesiveness, phagocytosis, and hexose monophosphate shunt activity by N-(2-mercapto-propionyl) glycine. <i>Research in Experimental Medicine</i> , 1981, 178, 257-262.	0.7	4
192	Serum-associated inhibition of neutrophil Fc receptors in cancer patients. <i>Journal of the National Cancer Institute</i> , 1981, 67, 803-7.	6.3	10
193	<i>In vitro</i> Effects of Synthetic Chemotactic Peptides on Neutrophil Function. <i>International Archives of Allergy and Immunology</i> , 1980, 62, 316-323.	2.1	14
194	Effects of Ascorbic Acid on Neutrophil Locomotion. <i>International Archives of Allergy and Immunology</i> , 1980, 61, 40-45.	2.1	19
195	Stimulation of granulocyte adhesiveness by the chemotactic peptide N-formyl-L-methionyl-L-phenylalanine. <i>Research in Experimental Medicine</i> , 1980, 177, 19-22.	0.7	4
196	Reversal by cimetidine of histamine-induced inhibition of true chemotaxis in neutrophil polymorphonuclears. <i>Research in Experimental Medicine</i> , 1980, 176, 201-205.	0.7	12
197	Neutrophil dysfunction and repeated infections: influence of levamisole and ascorbic acid. <i>British Journal of Dermatology</i> , 1980, 102, 49-56.	1.5	51
198	Stimulation of Neutrophil Locomotion by Inosiplex. <i>International Archives of Allergy and Immunology</i> , 1980, 62, 221-226.	2.1	6

#	ARTICLE	IF	CITATIONS
199	Alkaline Phosphatase Activity in Neutrophils of Chronic Myelocytic Leukemia Grown in Liquid Culture. <i>Acta Haematologica</i> , 1979, 62, 12-16.	1.4	4
200	Defective neutrophil chemotaxis and bactericidal power in a child with hyperimmunoglobulinemia E. <i>European Journal of Pediatrics</i> , 1979, 130, 181-187.	2.7	5
201	Lazy leukocyte syndrome. <i>Blut</i> , 1979, 39, 265-269.	1.2	8
202	Effects of irradiation and storage on granulocytes harvested by continuous-flow centrifugation. <i>Experimental Hematology</i> , 1979, 7, 131-6.	0.4	7
203	Buckley's syndrome. <i>British Journal of Dermatology</i> , 1978, 99, 569-572.	1.5	14